Search
for
Sort by
Research 31–60 of 302
- Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
- MODERN BIOLOGICAL TREATMENT METHODS FOR ALOPECIA AREATA: A COMPREHENSIVE REVIEW
- Trends and techniques: a statistical review of hair care product evaluation research
- Autoinmune Alopecia/Alopecia Areata
- The first 20 years of skin of color dermatology: An era of advancements in skin, hair, and nail disorders
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme
- Pediatric and Adolescent Alopecia Areata Treated with JAK Inhibitors: Balancing Efficacy and Safety Across Clinical Trials
- 42752 Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- Hair Growth-Supporting and Follicle-Protective Potential of a Botanical-Based Supplement Ingredient: In Vitro, Ex Vivo, and Molecular Docking Studies
- Mesenchymal stem/stromal cell therapy in atopic dermatitis and chronic urticaria: immunological and clinical viewpoints
- INIBIDORES DA JANUS QUINASE PARA O TRATAMENTO DA ALOPECIA AREATA
- Real World Evidence in Alopecia Areata: Current Management, Emerging Therapies and Future Challenges – A Narrative Review
- Alopecia Areata: Current and Emerging Therapies
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
- An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
- Ritlecitinib Efficacy in Adolescents With Alopecia Areata: A Real‐World Experience
- Determining meaningful thresholds for evaluating treatment efficacy in patients with alopecia areata
- Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
- Treatment preferences of adults and adolescents with alopecia areata: A discrete choice experiment
- Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Taiwanese Dermatological Association consensus on the diagnosis and management of alopecia areata
- Janus kinase inhibitors for alopecia areata: A narrative review
- Alopecia Areata: Pathogenesis, current treatments, and future perspectives
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- Alopecia areata: current concepts
- JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice